SCHEMBL1317544

SCHEMBL1317544

O=c1oc2cc(O)ccc2c2ccc([N+](=O)[O-])cc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.69
PKLR P30613 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
RXFP1 Q9HBX9 1/20 0.60
LMNA P02545 3/20 0.58
CA12 O43570 2/20 0.58
CA9 Q16790 2/20 0.58
MAPT P10636 5/20 0.56
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
CTDSP1 Q9GZU7 1/20 0.51
HSD17B3 P37058 2/20 0.50
TDP1 Q9NUW8 2/20 0.49
RAB9A P51151 1/20 0.49
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 3/20 0.49
HSD17B10 Q99714 2/20 0.49
ALOX15 P16050 1/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5332842 0.89 MAPT (0.63) PDE2ACA12CA9MAPTMEN1
SCHEMBL29401099 0.82 PDE2A (1.00) PDE2APKLRNPSR1RXFP1LMNA
SCHEMBL29368885 0.82 PDE2A (1.00) PDE2APKLRNPSR1RXFP1LMNA
SCHEMBL803408 0.82 PDE2A (1.00) PDE2APKLRNPSR1RXFP1LMNA
SCHEMBL12298179 0.82 LMNA (0.60) PDE2ALMNACA12CA9MAPT
SCHEMBL12113006 0.82 MAPT (0.71) NPSR1RXFP1LMNACA12CA9
SCHEMBL2990038 0.80 MAPT (0.73) NPSR1RXFP1LMNAMAPTMEN1
SCHEMBL6720509 0.77 CA9 (0.56) PKLRLMNACA12CA9MAPT
SCHEMBL6718661 0.77 AR (0.55) LMNACA12CA9MAPTMEN1
SCHEMBL6480372 0.77 PDE2A (0.56) PDE2APKLRNPSR1RXFP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2319835-B1 GLUCOCORTICOID RECEPTOR AGONIST COMPOSED OF 2,2,4-TRIMETHYL-6-PHENYL-1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED OXY GROUP AYUMI PHARMACEUTICAL CORP (JP) 2016-04-13 EP disclosed
EP-2319835-B1 GLUCOCORTICOID RECEPTOR AGONIST COMPOSED OF 2,2,4-TRIMETHYL-6-PHENYL-1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED OXY GROUP AYUMI PHARMACEUTICAL CORP (JP) 2016-04-13 EP disclosed
US-9029572-B2 3-hydroxy-6H-benzo [C] chromene-6-one derivative and manufacturing method thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2015-05-12 US disclosed
US-9029572-B2 3-hydroxy-6H-benzo [C] chromene-6-one derivative and manufacturing method thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2015-05-12 US disclosed
US-20140296540-A1 3-HYDROXY-6H-BENZO [C] CHROMENE-6-ONE DERIVATIVE AND MANUFACTURING METHOD THEREOF AYUMI PHARMACEUTICAL CORPORATION (JP) 2014-10-02 US disclosed
US-20140296540-A1 3-HYDROXY-6H-BENZO [C] CHROMENE-6-ONE DERIVATIVE AND MANUFACTURING METHOD THEREOF AYUMI PHARMACEUTICAL CORPORATION (JP) 2014-10-02 US disclosed
US-8802869-B2 3-hydroxy-6H-benzo [c] chromene-6-one derivative and manufacturing method thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2014-08-12 US disclosed
US-8802869-B2 3-hydroxy-6H-benzo [c] chromene-6-one derivative and manufacturing method thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2014-08-12 US disclosed
US-20130310576-A1 3-HYDROXY-6H-BENZO [C] CHROMENE-6-ONE DERIVATIVE AND MANUFACTURING METHOD THEREOF SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-11-21 US disclosed
US-8580784-B2 Method for treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-11-12 US disclosed
US-20090298827-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-03 US disclosed
US-20090298827-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-03 US disclosed
US-20090298827-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-03 US disclosed
WO-2009139361-A1 GLUCOCORTICOID RECEPTOR AGONIST COMPOSED OF 2,2,4-TRIMETHYL-6-PHENYL-1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED OXY GROUP 参天製薬株式会社 (JP) 2009-11-19 WO disclosed
EP-2085389-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS Santen Pharmaceutical Co., Ltd (JP) 2009-08-05 EP disclosed
EP-2085389-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS Santen Pharmaceutical Co., Ltd (JP) 2009-08-05 EP disclosed
EP-2085387-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS Santen Pharmaceutical Co., Ltd (JP) 2009-08-05 EP disclosed
EP-2085387-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLCHALCOGENO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS Santen Pharmaceutical Co., Ltd (JP) 2009-08-05 EP disclosed
EP-2085388-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS Santen Pharmaceutical Co., Ltd (JP) 2009-08-05 EP disclosed
EP-2085388-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS Santen Pharmaceutical Co., Ltd (JP) 2009-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298827-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS NR3C1, NR3C2, MC2R PDE2A 701/4885PKLR 2946/4885NPSR1 102/4885
US-20140296540-A1 3-HYDROXY-6H-BENZO [C] CHROMENE-6-ONE DERIVATIVE AND MANUFACTURING METHOD THEREOF CYP8B1, CTRC, CYP7B1 PDE2A 3327/4885PKLR 4651/4885NPSR1 3900/4885
US-20130310576-A1 3-HYDROXY-6H-BENZO [C] CHROMENE-6-ONE DERIVATIVE AND MANUFACTURING METHOD THEREOF CYP8B1, CTRC, CYP7B1 PDE2A 3327/4885PKLR 4651/4885NPSR1 3900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.